Skip to main content
Scientist talking at a podium to group at a conference.
Working with Us

2019 PD Therapeutics Conference

  • Register Now
About the Conference
Male speaker at podium for the 2017 Parkinson's Disease Therapeutics Conference

The Parkinson's Disease Therapeutics Conference is The Michael J. Fox Foundation's annual scientific conference and the only one in the world focused exclusively on Parkinson's disease drug development. The 13th Annual PD Therapeutics Conference will be held on October 15, 2019 at Convene Midtown East, New York City.

We are delighted to have Richard Hargreaves, PhD, Corporate VP, Neuroscience at Celgene chair our 2019 event.

The PD Therapeutics Conference brings together 300 research and business development professionals from both academia and industry and showcases the most exciting and innovative research from MJFF's research portfolio. Novel advances in basic and translational research from both academic and industry labs are highlighted through speaker presentations and a poster session. The event is a platform for field leaders to share new and unpublished results and for fostering new relationships and collaborations.

Registration for our 2019 conference is now open.

Convene Conference Center
730 Third Ave. (Between 45th and 46th Streets
New York, NY 10017

For questions,

Please contact researchmeetings@michaeljfox.org.


Conference Schedule
7:45 - 8:30
Breakfast
Illustrated stack of pancakes.
8:30 - 9:00
Welcome
by Todd Sherer, PhD and Richard Hargreaves, PhD
9:00 - 9:50
Emerging Targets and Novel Therapeutic Approaches
Ashley S. Harms, PhD, University of Alabama at Birmingham
CD4 T Cell Dependent Neurotoxicity in an Alpha-synuclein Model of Parkinson's Disease
Daniel Kacy Cullen, PhD, University of Pennsylvania
Tissue-Engineered Nigrostriatal Pathway for Anatomical Tract Reconstruction in Parkinson's Disease
9:50 - 10:40
Disease Mechanisms and Converging Biology (Part 1)
J. Timothy Greenamyre, MD, PhD, University of Pittsburgh
Parkinson’s Disease: Where Genes and Environment Meet
Miratul Muqit, MD, PhD, University of Dundee
Investigation of the Role of PINK1-Dependent Phosphorylation of Rab GTPases in Parkinson's Disease
10:40 - 11:10
Networking Break/Poster Viewing
11:10 - 12:00
Disease Mechanisms and Converging Biology (Part 2)
Sergio Pablo Sardi, PharmD, PhD, Sanofi Genzyme
GBA-Related Biomarkers in Parkinson’s Disease
Poul Henning Jensen, MD, PhD, The Danish Research Institute of Translational Neuroscience
Novel Alpha-synuclein Pathology in Parkinson’s Disease and MSA and New Tools for Investigating Alpha-synuclein Aggregates
12:00 - 1:00
Lunch/Poster Viewing
Illustrated hand serving plate with domed cover.
1:00 - 2:45
Trial Design, Clinical Studies and Insights From PD Cohorts
Ira Shoulson, MD, Grey Matter
The Parkinson’s Disease Patient Report of Problems (PD-PROP): ): Application of Natural Language Processing, Expert Curation, and Machine Learning
Tatiana Foroud, PhD, Indiana University and Tanya Simuni, MD, Northwestern University
Recruitment and Clinical Evaluation of LRRK2 and GBA Carriers in The Parkinson’s Progression Markers Initiative
Jan Stoehr, PhD, AC Immune
Development of an Alpha-synuclein PET Tracer
Karl Kieburtz, MD, MPH, University of Rochester
Challenges in Improving the Efficiency of Parkinson’s Disease Therapeutic Development
2:45 - 3:15
Networking Break/Poster Viewing
3:15 - 4:15
Hot Topics in Parkinson's Disease Research
Kenneth Marek, MD, Institute for Neurodegenerative Disorders
Parkinson's Progression Markers Initiative 2.0: New Science, New Cohorts - Focus on Prodromal PD
Tanya Simuni, MD, Northwestern University
Hope Versus Hype: The Future of Repurposing Trials in Parkinson’s Disease
4:15 - 4:30
Closing Remarks
4:30 - 6:00
Cocktail Reception/Poster Viewing
Illustrated martini.
Illustrated male avatar.

Richard Hargreaves

Richard Hargreaves, PhD, is Corporate VP, Neuroscience at Celgene. Dr. Hargreaves previously held positions at Biogen and Merck and has decades of experience in the development of drug candidates and PET imaging agents for neuroscience indications.

Speakers

  • Illustrated male avatar.

    Daniel Kacy Cullen, PhD

    Research Associate Professor Of Neurosurgery, University of Pennsylvania School of Medicine

  • Illustrated female avatar.

    Tatiana Foroud, PhD

    Chair, Department of Medical and Molecular Genetics, Indiana University

  • Illustrated male avatar.

    J. Timothy Greenamyre, MD, PhD

    Professor of Neurology; Chief, Movement Disorders Division; Director, Pittsburgh Institute for Neurodegenerative Diseases (PIND) at the University of Pittsburgh

  • Illustrated female avatar.

    Ashley S. Harms, PhD

    Assistant Professor, Department of Neurology, University of Alabama at Birmingham

  • Illustrated male avatar.

    Poul Henning Jensen, MD, PhD

    Professor and Core Group Leader, The Danish Research Institute of Translational Neuroscience 

  • Illustrated male avatar.

    Karl Kieburtz, MD, MPH

    Robert J. Joynt Professor in Neurology, Senior Associate Dean for Clinical Research, Director of the Clinical & Translational Science Institute at the University of Rochester Medical Center

  • Illustrated male avatar.

    Kenneth Marek, MD

    President and Senior Scientist at The Institute for Neurodegenerative Disorders

  • Illustrated male avatar.

    Miratul Muqit, MD, PhD

    Professor, School of Life Sciences, University of Dundee

  • Illustrated male avatar.

    Sergio Pablo Sardi, PharmD, PhD

    Research & Development Director, Neurobiology Unit, Sanofi Genzyme

  • Illustrated male avatar.

    Ira Shoulson, MD

    Co-Founder and Principal, Grey Matter

  • Illustrated female avatar.

    Tanya Simuni, MD

    Chief of Movement Disorders in the Department of Neurology; Arthur C. Nielsen, Jr., Research Professor of Parkinson's Disease and Movement Disorders; Professor of Neurology, Northwestern University

  • Illustrated male avatar.

    Jan Stoehr, PhD

    Head of Non-Alzheimer's Disease Proteinopathies, AC Immune

Posters
  • Michael Schwarzschild, MD, PhD

    Massachusetts General Hospital

    Featured Poster: Results from the SURE-PD3 Trial 

  • Roger Albin, MD

    University of Michigan

    Alpha4Beta2 Nicotinic Agonist for Treatment of L-Dopa Refractory Gait and Balance Disorders in Parkinson's Disease

  • Rosa Canet-Aviles, PhD

    Foundation for the National Institutes of Health (FNIH)

    AMP PD: Collaborating in the Discovery of Biomarkers to Accelerate the Development of Therapies for Parkinson's Disease

  • Matthew Havrda, PhD

    Geisel School of Medicine at Dartmouth

    Plasma-borne Pyroptosis-related Protein NLRP3 Associated with Parkinson’s Disease

  • Lorraine Iacovitti, PhD

    Thomas Jefferson University 

    Validating Astrocyte-Produced Protein GDF15 as a Novel Neuroprotective Therapy

  • Zachary Kabelac, PhD

    Massachusetts Institute of Technology

    Observational Study of Emerald Related to Mobility in Parkinson’s Patients

  • Heather Lasseter, PhD

    Cohen Veterans Biosciences

    RAPID-Dx Inflammatory Markers Platform Comparison Study

  • Sakura Minami, PhD

    Alkahest, Inc.

    Targeting the Eotaxin/CCR3 Pathway in Mouse Models of Parkinson’s Disease

  • Inga Peter, PhD

    Icahn School of Medicine at Mount Sinai

    Genetic, Clinical, and Therapeutic Links Between Crohn’s Disease and Parkinson’s Disease 

  • Erik Stoops, PhD

    ADx Neurosciences

    Optimizing Standard Operating Procedures for Analysis of Alpha-Synuclein in Biological Fluids: A Data-Driven Approach

  • Marcus Unger, MD

    Saarland University

    The Effect of Resistant Starch on Bowel Habits, Short Chain Fatty Acids, and Gut Microbiota in Parkinson’s Disease - The RESISTA-PD Trial

  • Fei Wang, PhD

    Weill Cornell Medicine

    Identification of Comprehensive Progression PD Subtypes with PPMI 

Conference Sponsors
PDTC sponsor logos

Interested in Sponsorship Opportunities?

Contact our Stakeholder Engagement team at researchpartnerships@michaeljfox.org for information about 2019 sponsorship opportunities.

About the Venue

Address

Convene Conference Center
730 Third Ave. (Between 45th and 46th Streets)
New York, NY 10017

Speaker on stage with panelists at the Parkinson's Disease Therapeutics Conference.

Convene at 730 Third Avenue is an incredible event space in Midtown East that is sure to impress your participants. One of our largest locations, it's perfect for your next town hall, conference, or reception and can seat up to 430 people in the Wharton Forum. The column-free, two-story room has 30 foot ceilings, with plenty of natural light and unobstructed and iconic views of Manhattan. As the first-ever Convene property and part of the company's signature collection, this property offers 40,000 square feet of space, with easy flow from the Forum space to 12 different breakout rooms which is ideal for multi-day events or trainings. Located just two blocks from Grand Central Terminal, 730 Third Avenue currently hosts the world's most important meetings and iconic events, from the James Beard Awards to attendees from the United Nations. 


Stay up to Date

Sign up to receive all conference related updates in your inbox.

We use cookies to ensure that you get the best experience. By continuing to use this website, you indicate that you have read our Terms of Service and Privacy Policy.